Evidence map›Paper›PMID 35806053›Full record

ArticleInternational journal of molecular sciences2022

Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents.

Alberto Pla-López, Raquel Castillo, Rocío Cejudo-Marín, Olaya García-Pedrero, Mariam Bakir-Laso, Eva Falomir, Miguel Carda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Synthesis and Biological Evaluation of Potential Oncoimmunomodulator Agents.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Alberto Pla-LópezInorganic and Organic Chemistry Department, Universidad Jaume I, 12071 Castellón, Spain.
Raquel CastilloPhysical and Analytical Chemistry Department. Universidad Jaume I, 12071 Castellón, Spain.ORCID 0000-0003-1597-1136
Rocío Cejudo-MarínPredepartmental Medicine Unit, Universidad Jaume I, 12071 Castellón, Spain.
Olaya García-PedreroInstituto de Química Organometálica Enrique Moles, Centro de Innovación en Química Avanzada, Universidad de Oviedo, 33006 Oviedo, Spain.
Mariam Bakir-LasoInstituto Universitario de Investigación en Ciencias Ambientales de Aragón (IUCA), Universidad de Zaragoza, 50009 Zaragoza, Spain.
Eva FalomirInorganic and Organic Chemistry Department, Universidad Jaume I, 12071 Castellón, Spain.ORCID 0000-0003-0329-6313
Miguel CardaInorganic and Organic Chemistry Department, Universidad Jaume I, 12071 Castellón, Spain.
Universitat Jaume I · ESUniversidad de Oviedo · ESUniversidad de Zaragoza · ES

Funding

Generalitat Valenciana ACIF/2020/341Ministerio de Economía y Competitividad project RTI2018-097345-B-I00Universitat Jaume I projects UJI-B2018-38 and UJI-B2019-43
6 · The paper itself

Abstract

Twenty-six triazole-based derivatives were designed for targeting both PD-L1 (programmed death receptor ligand 1) and VEGFR-2 (vascular endothelial growth factor receptor 2). These compounds were synthetized and biologically evaluated as multitarget inhibitors of VEGFR-2, PD-L1 and c-Myc proteins. The antiproliferative activity of these molecules on several tumor cell lines (HT-29, A-549, and MCF-7) and on the non-tumor cell line HEK-293 was determined. The effects on the abovementioned biological targets were evaluated for some selected compounds. Compound

Indexed as

Antineoplastic AgentsVascular Endothelial Growth Factor Receptor-2B7-H1 AntigenCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHEK293 CellsHumansMolecular Docking SimulationProto-Oncogene Proteins c-mycStructure-Activity RelationshipTriazolesVascular Endothelial Growth Factor AAntineoplastic AgentsB7-H1 AntigenProto-Oncogene Proteins c-mycTriazolesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2angiogenesisc-Mycflow cytometryimmunomodulationmultitarget inhibitorsnon-peptidic small moleculesPD-L1VEGFR-2

Identifiers

PMID35806053
PMCPMC9266368
OpenAlexW4283522509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.